Press release
Metastatic Castration-Resistant Prostate Cancer Market is expected to reach USD 20.8 billion by 2034
Metastatic Castration-Resistant Prostate Cancer
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70869
Over the next decade, the mCRPC market is set to expand significantly due to the growing adoption of novel androgen receptor inhibitors, targeted therapies, and immunotherapies, alongside advances in precision medicine and biomarker-driven treatment strategies.
Market Overview
• Market Size (2024): USD 12.4 billion
• Forecasted Market Size (2034): USD 20.8 billion
• CAGR (2024-2034): ~5.3%
• Key Drivers: Rising incidence of prostate cancer in aging populations, increased use of genomic profiling, and expanded indications for advanced therapies.
• Challenges: Treatment resistance, high drug costs, and limited access in emerging economies.
• Leading Players: Johnson & Johnson, Pfizer Inc., Astellas Pharma Inc., Bayer AG, Bristol Myers Squibb, Sanofi S.A., and Merck & Co.
Segmentation Analysis
By Drug Class
• Androgen Receptor Signaling Inhibitors (Enzalutamide, Apalutamide, Darolutamide)
• Chemotherapy (Docetaxel, Cabazitaxel)
• Radiopharmaceuticals (Radium-223, Lutetium-177-PSMA-617)
• Immunotherapy (Sipuleucel-T, PD-1/PD-L1 inhibitors)
• Targeted Therapy (PARP inhibitors - Olaparib, Rucaparib)
By Biomarker Status
• BRCA1/2-Mutated
• MSI-High/dMMR
• Other Biomarker-Positive
• Biomarker-Negative
By End Use
• Hospitals & Cancer Centers
• Specialty Clinics
• Academic & Research Institutes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Segmentation Summary
Androgen receptor inhibitors remain the backbone of mCRPC treatment, but PARP inhibitors for BRCA-mutated cases and radioligand therapies are emerging as key growth drivers.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70869/metastatic-castration-resistant-prostate-cancer-market
Regional Analysis
North America
• Holds ~47% of global revenue in 2024.
• High adoption of next-generation hormonal therapies and access to genomic testing.
Europe
• Strong clinical research presence and reimbursement support for advanced therapies.
• EMA approvals expanding targeted therapy use.
Asia-Pacific
• Fastest-growing region (CAGR > 7%).
• Rising incidence in Japan, China, and South Korea, coupled with improving access to genomic diagnostics.
Middle East & Africa
• GCC nations increasing investment in oncology infrastructure.
• Limited biomarker testing availability in low-income regions.
Latin America
• Brazil and Mexico leading in therapy adoption and clinical trial participation.
Regional Summary
North America leads in advanced treatment uptake, but Asia-Pacific will experience the fastest growth due to rising prostate cancer incidence and healthcare modernization.
Market Dynamics
Key Growth Drivers
1. Precision oncology adoption for biomarker-selected treatments.
2. Novel AR inhibitors with better efficacy and safety profiles.
3. Approval of radioligand therapies improving outcomes in late-stage disease.
4. Combination therapy research targeting resistance mechanisms.
Key Challenges
1. Therapy resistance after prolonged use of AR inhibitors.
2. High cost of advanced treatments.
3. Limited access to genomic testing in some regions.
4. Adverse effects impacting long-term treatment adherence.
Latest Trends
• PSMA-targeted radioligand therapy gaining global approvals.
• Expansion of PARP inhibitor combinations in earlier disease settings.
• Research into bispecific antibodies for prostate cancer.
• Use of AI in imaging for better detection and monitoring.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70869
Competitor Analysis
Major Players
• Johnson & Johnson (Zytiga®, Erleada®)
• Pfizer Inc. & Astellas Pharma Inc. (Xtandi®)
• Bayer AG (Nubeqa®, Xofigo®)
• Bristol Myers Squibb
• Sanofi S.A. (Jevtana®)
• Merck & Co., Inc. (Keytruda®)
• Clovis Oncology (Rubraca®)
• Novartis AG (Pluvicto® - radioligand therapy)
• AstraZeneca plc (Lynparza® - PARP inhibitor)
• Myovant Sciences
• Telix Pharmaceuticals
• Blue Earth Diagnostics
• Amgen Inc.
• Ipsen
• Genmab A/S
Competitive Summary
The mCRPC market is highly competitive, with pharma giants focusing on combination regimens and precision-targeted approaches to overcome resistance and improve survival outcomes.
Conclusion
The metastatic castration-resistant prostate cancer market is set for steady expansion through 2034, driven by precision medicine, targeted agents, and novel radioligand therapies.
Opportunities include:
• Expanding biomarker testing programs to guide treatment.
• Developing resistance-proof AR inhibitors.
• Improving affordability and access in emerging markets.
This report is also available in the following languages : Japanese (転移性去勢抵抗性前立腺がん市場), Korean (전이성 거세 저항성 전립선암 시장), Chinese (转移性去势抵抗性前列腺癌市场), French (Marché du cancer de la prostate métastatique résistant à la castration), German (Markt für metastasierten kastrationsresistenten Prostatakrebs), and Italian (Mercato del cancro alla prostata metastatico resistente alla castrazione), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/70869/metastatic-castration-resistant-prostate-cancer-market#request-a-sample
Our More Reports:
Benign prostatic hyperplasia Market
https://exactitudeconsultancy.com/reports/70812/benign-prostatic-hyperplasia-market
Premature Market
https://exactitudeconsultancy.com/reports/70814/premature-market
Erectile Dysfunction Devices Market
https://exactitudeconsultancy.com/reports/70816/erectile-dysfunction-devices-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Castration-Resistant Prostate Cancer Market is expected to reach USD 20.8 billion by 2034 here
News-ID: 4144016 • Views: …
More Releases from Exactitude Consultancy
Multiple Myeloma Market is expected to reach USD 46.3 billion by 2034
Multiple myeloma (MM) is a hematologic malignancy characterized by the uncontrolled proliferation of plasma cells in the bone marrow. It is the second most common blood cancer after non-Hodgkin lymphoma and is associated with bone pain, anemia, renal dysfunction, and increased susceptibility to infections.
Over the next decade, the multiple myeloma market is expected to see substantial growth driven by immunotherapies, proteasome inhibitors, monoclonal antibodies, and CAR-T cell therapy. Advances in…
Malignant Pleural Mesothelioma Market is expected to reach USD 2.11 billion by 2 …
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural lining of the lungs, most often caused by prolonged asbestos exposure. It is associated with a poor prognosis due to late-stage diagnosis and limited curative options. Traditionally treated with surgery, chemotherapy, and radiation, the MPM market is undergoing transformation as immunotherapy, targeted agents, and advanced imaging gain traction.
Download Full PDF Sample Copy of Market Report…
Low-Grade Glioma Market is expected to reach USD 2.75 billion by 2034
Low-grade gliomas (LGGs) are slow-growing primary brain tumors classified as WHO grade I or II, most commonly including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. Although generally associated with better prognosis compared to high-grade gliomas, LGGs can progress to higher grades over time, necessitating long-term management.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70865
The LGG market is set for significant growth over the next decade, driven by advances in molecular profiling,…
Intrahepatic Cholangiocarcinoma Market is expected to reach USD 1.34 billion by …
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive form of bile duct cancer originating within the liver. It accounts for approximately 10-15% of primary liver cancers but has one of the poorest prognoses due to late-stage diagnosis and limited treatment options. Over recent years, genomic profiling has identified actionable mutations-including FGFR2 fusions, IDH1 mutations, and BRAF mutations-leading to the approval of targeted therapies and expanding treatment possibilities.
The iCCA market is…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
